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Abstract: Flavonoids are polyphenolic compounds classified into flavonols, flavones, 
flavanones, isoflavones, catechins, anthocyanidins, and chalcones according to their 
chemical structures. They are abundantly found in Nature and over 8,000 flavonoids have 
from different sources, mainly plant materials, have been described. Recently reports have 
shown the valuable effects of flavonoids as antiviral, anti-allergic, antiplatelet, antitumor, 
antioxidant, and anti-inflammatory agents and interest in these compounds has been 
increasing since they can be helpful to human health. Several mechanisms of action are 
involved in the biological properties of flavonoids such as free radical scavenging, 
transition metal ion chelation, activation of survival genes and signaling pathways, 
regulation of mitochondrial function and modulation of inflammatory responses. The  
anti-inflammatory effects of flavonoids have been described in a number of studies in the 
literature, but not frequently associated to respiratory disease. Thus, this review aims to 
discuss the effects of different flavonoids in the control of lung inflammation in some 
disorders such as asthma, lung emphysema and acute respiratory distress syndrome and the 
possible mechanisms of action, as well as establish some structure-activity relationships 
between this biological potential and chemical profile of these compounds. 
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1. Introduction 
Flavonoids are cytoprotective compounds that are present in dietary plants and vegetables. The  
anti-inflammatory and antioxidant properties of flavonoids make them likely candidates for evaluation 
for the treatment of inflammatory diseases including pulmonary diseases [1–4]. In addition, flavonoids 
afford cellular protection by inhibiting enzymes involved in cell proliferation and modulating  
the expression of proteins associated with apoptosis [5]. In the current review, we focus on the  
anti-inflammatory activity of flavonoids with respect to respiratory illness and correlate the structural 
and functional relationship of these compounds.  
2. Chemistry and Occurrence of Flavonoids 
Flavonoids, the most important class of phenolic compounds, are secondary metabolites produced 
by plants and are found in a non-glycosylated form (aglycone) or attached to a sugar molecule 
(glycoside) [1]. All flavonoids display a common structure of two aromatic rings connected to three 
carbon atoms (C6'C3'C6). These compounds frequently displayed hydroxylation at positions 5 and 7 
and the B ring and oxidation at the 4'-, 3',4'-, or 3',4',5'- positions due to their biosynthesis routes [6]. 
Flavonoids are widely found in Nature and present an important chemical diversity mainly because of 
the variations in the positions of B and C rings and the degree of hydroxylation, oxidation and 
saturation, of C ring. Flavonoids are generally classified according to their chemical structures into 
chalcones, flavanones, flavanonols, flavones, flavonols, isoflavones, flavan-3-ols (or catechins), and 
anthocyanidins [7–9], as shown in Figure 1. Structures of the various flavonoids mentioned in this 
review are presented in Figure 2. 
Figure 1. Classification of flavonoids based on their chemical structure. 
 
Chalcones, considered to be the precursors of flavonoids, consist of two aromatic rings connected 
by three carbons to form an α,β-unsaturated carbonyl system. After the C ring is closed to form a 
chromone unit, flavanones are formed. Flavanones display a carbonyl group in position C-4 as shown 
in the structures of naringin (1), naringenin (2), taxifolin (3), eriodictyol (4) and hesperidin (5). 
Oxidation at the C-3 position produces the flavonols kaempferol (12) and quercitrin (13).  
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Figure 2. Chemical structures of flavonoids 1–50.  
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A double bond at C-2, formed through dehydration, produces flavones such as chrysin (14), 
apigenin (15) and rutin (16) as well as isoflavones such as genistin (41), genistein (42) daidzin (43), 
and daidzein (44). The action of reductases on flavonols produces flavan-3-ols such as catechin (46), 
epicatechin (47), and epigallocatechin gallate (48), and the colorful anthocyanidins, such as apigenidin 
(49) and cyanidin (50). 
More than 8,000 different types of flavonoids have been described in Nature. These compounds, 
usually described as glycoside forms (e.g., glucosides, rhamnoglucosides, and rutinosides), are found in our 
daily diet in fruits, vegetables, grains, seeds, bark, herbs, roots, flowers, stems, and spices [7,10–12]. The 
consumption of flavonoids not only occurs through intake of vegetables, but also by drinking 
beverages such as wine, tea and coffee [13]. These polyphenols have a wide variety of physiological 
functions in plants raging from affecting plant pigmentation, flavor, growth and reproduction to 
providing an innate immunity and resistance against pathogens (bacterial, fungal and viral) and also 
protection against herbivores and insects [1]. Flavonoids are also involved in electron transport during 
photosynthesis, acting as an antioxidant against the effects of ultraviolet light [14,15]. In addition, a 
wide variety of commercially available drugs have had their active compounds discovered from 
naturally occurring products [16,17]. 
3. General Aspects and Structure-Activity of Flavonoids in the Oxidative Stress  
Oxidative stress initiates a number of pathologic processes, including airway inflammation which is 
involved in the pathogenesis and also in exacerbation of pulmonary disease. The antioxidant defense 
mechanism includes enzymes such as superoxide dismutase, catalase and glutathione peroxidase. 
Flavonoids have been recognized as antioxidants because they protect against injuries caused by free 
radicals, and it has been suggested that flavones and flavan-3-ols are the most effective against reactive 
oxygen species [12]. The role of any particular phenolic antioxidant is directly associated with the 
capacity of the hydrogen radical donation from the phenolic group and the presence of an unpaired 
electron in the aromatic ring.  
The antioxidant activity of the non-glycosylated flavonoids is related to the number of hydroxyl 
groups present in the molecule [12]. However, the presence of a third hydroxyl group at the B ring at 
C-5 position on the structure of myricetin (17) does not increase its efficiency in comparison with 
quercetin (18). This suggests that the occurrence of three hydroxyl groups in the aromatic nucleus does 
not increase the efficiency of an antioxidant molecule. The presence of a hydroxyl group at the B ring 
of the chemical structure of kaempferol (12) could explain the low antioxidant activity of kaempferol 
(12), despite the presence of a conjugated double bond and the 3-OH group [18,19]. Other structural 
characteristic that influence the antioxidant activity are the 3'- and 4'-OH groups because the addition 
of hydroxyl groups to carbon atoms in the ortho position appear to further enhance the antioxidant 
capacity [19]. Several studies examining the activity [20–23] and structural characteristic of flavonoids 
have shown antioxidant and free radical scavenging properties. Three structurally important features 
are involved: (A) an ortho-dihydroxyl (catechol) group at the B ring, (B) a Δ2 double bond combined 
with a 4-oxo group in the C ring, and (C) hydroxyl groups at the C-3 and C-5 positions [24]. 
Additionally, evidence in the literature has showvn that non-glycosylated derivatives such as 
quercetin (18), luteolin (19), myricetin (17) and kaempferol (12) displayed a higher antioxidant 
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capacity than the related flavonoids quercitrin (13), rutin (16) and astragalin (20) [25]. A previous 
study [26] demonstrated that quercetin glycosides have lower antioxidant activity than quercetin 
aglycone in an artificial membrane system, suggesting that glycosylation weakens declines the 
antioxidant effect of flavonoids. This reduction may be result of increased blockage of the phenolic 
groups responsible for removing radicals and metal chelating agents and perhaps to a decrease of 
accessibility of the membranes due to the large glycoside group. Higher oligomers have antioxidant 
potentials, and monomers have not as much of an effect [27]. 
Flavonols and flavones have similar structures but the lack of a 3-OH functional group in flavones 
is related to their low antioxidant activity. This statement is reinforced by a study [18] which describes 
the significant reduction of antioxidant activity (assessed by the Trolox equivalent antioxidant  
capacity—TEAC assay) of hyperoside (39), in which the 3-OH group in the C ring and the  
3',4'-dihydroxy unit in the B ring are maintained. This study also proposes that the existence of a sugar 
moiety at position C-8 of the compound vitexin (21) significantly decreases antioxidant efficacy 
compared with the non-glycosylated derivative [18]. Other studies also show that substituting the  
3-OH group with a methyl group decreases the activity of the glycosyl derivatives of quercetin (18) 
and kaempferol (12) against heat-induced oxidation by β-carotene and linoleic acid and affects the 
conformation of the molecule [28]. Moreover in a chemical scavenging study, Bors et al. [20] also 
showed that flavan-3-ols and flavonols are powerful antioxidants as a result of the presence of a 3-OH 
associated with the 3',4'-dihydroxyl (catechol) unit. Otherwise, the absence of the double bond 
decreases the antioxidant efficacy of flavanones (naringenin, 2) in contrast to flavones (apigenin, 15) 
and flavonols (quercetin, 18).  
In addition, in vivo, certain flavonoids can remove superoxides directly, while others can remove 
the abundantly reactive peroxynitrite radicals [29–31]. Currently, studies show that the flavonoids 
quercetin (18), silibin (40) and luteolin (19) are the most potent inhibitors of xanthine oxidase [32]. 
Furthermore, flavonoids have the ability to chelate iron [33] and reduce the activation of the 
complement system thus reducing the adhesion of inflammatory cells to the endothelium [34], as 
shown using microvascular methods in vitro and in vivo. In addition, these compounds can inhibit the 
metabolism of arachidonic acid and reduce the peroxidase release, which in turn inhibits the 
production of reactive oxygen species by neutrophils by α1-antitrypsin activation [35]. Moreover, 
some flavonoids can chelate transition metal ions which are responsible for the production of reactive 
oxygen species and inhibit the lipoxygenase reaction. Zhu et al. [36] suggested that flavonoids also 
displayed an in vivo antioxidant capacity by the non-transition oxidation of the metal-dependent ions. 
Flavonoids may also have antioxidant properties through the protection or improvement of 
endogenous antioxidants. Many of these compounds reduce oxidative stress by stimulating 
glutathione-S-transferase (GST), an enzyme that protects cells of the damage caused by free radicals 
by inducing oxidative stress resistance [37]. Because of this ability to reduce oxidation, flavonoids 
have been extensively tested in several studies of diseases that involve the oxidative stress, justifying 
the use of these compounds in folk medicine.  
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4. General Aspects and the Role of Flavonoids in the Inflammation 
Inflammation is a response to a cellular injury induced by physical stress, infectious agents,  
toxins, and other factors. Whereas an acute inflammatory reaction is important to the immune  
response and could culminate in a resolution of the injury, chronic inflammation can cause tissue 
destruction and are involved in the pathogenesis of autoimmune, neurodegenerative and respiratory 
diseases. The inflammatory response is part of the innate immune response. After an injury, the acute 
response mainly involves macrophage activation, which is a source of mediators such as histamine. 
Macrophages and other cells release pro-inflammatory cytokines such as tumor necrosis factor (TNF-), 
interleukin-1 (IL-1) and IL-6, which trigger the inflammatory cascade by acting on end-organ 
receptors in response to injury [38,39]. These pro-inflammatory cytokines can induce endothelial cell 
leukocyte adhesion, the release of proteases the release of arachidonic acid metabolites, and the 
activation of the coagulation cascade [40]. Additionally, counter-regulatory and anti-inflammatory 
cytokines such as IL-10 provide a negative feedback system to counteract inflammatory cascade 
activation [41]. 
Clinical and classical signals of inflammation are an increase in temperature, redness, swelling, and 
pain and tissue/organ dysfunction. The acute phase response is characterized by platelet adhesion, 
vasoconstriction of efferent vessels, afferent vascular dilation induced by cytokines release, activation 
of the complement and fibrinolytic systems, and the initiation of the leukocyte adhesion cascade. An 
increase in endothelial gaps allows extravasation of serum proteins (exudate) and leukocytes and 
culminates in tissue swelling and phagocytosis of foreign material with pus formation (Figure 3).  
Several inflammatory mediators are released during injury such as histamine, prostaglandins, 
thromboxanes and leukotrienes, as well as cytokines and nitric oxide [42,43]. Nitric oxide (NO) is 
produced when the amino acid L-arginine is converted in L-citrulline by nitric oxide synthase [44] 
using NG-hydroxyl-L-arginine as an intermediate [38]. Three NOS isoforms were described (two 
constitutive and one inducible): the neuronal or type I (nNOS), the inducible isoform or type II 
(iNOS), and the endothelial isoform or type 3 (eNOS) which is released primarily by endothelial cells 
of the injured tissue and exerts cytotoxic activity against microorganisms [38]. However, it has been 
previously demonstrated that in pathological situations, NO can be produced by the inducible isoform 
in high quantities and can affect lung inflammation [45,46]. Therefore, oxidative stress and nitrative 
stress are involved in the pathogenesis of inflammatory diseases [47].  
The organism can resolve the inflammatory response per se (Figure 3). However, if the  
stimulus persists, a vicious cycle can be created, which involves the release of more and more 
cytokines, which in turn damages the tissue and induces the recruitment of more and more 
inflammatory cells, which causes the release of more cytokines and perpetuating the inflammation. 
Chronic inflammation is associated with various pathological situations including lung diseases, and is 
characterized by angiogenesis, mononuclear cell infiltrate and fibrosis and involves the release of 
several pro-inflammatory mediators.  
Prostaglandins (PGs) play a key role in the inflammatory response since an increased in PG 
biosynthesis is observed in inflamed tissue. The prostanoids PGs and thromboxane A2 (TXA2), are 
derived from the arachidonic acid (AA), a 20-carbon unsaturated fatty acid. Phospholipases release 
AAs in plasma membrane which are metabolized by the sequential actions of prostaglandin synthase or 
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by cyclooxygenase (COX), which are found in two distinct isoforms known as COX-1 and COX-2 [48]. 
Commercially available drugs with anti-inflammatory effects are the most commonly used for 
inhibiting the COX enzyme to prevent the formation of inflammatory mediators such as prostaglandins 
and thromboxanes [49]. However, it is well known that these drugs trigger several adverse effects 
mainly because of the use of high doses and prolonged treatment.  
Figure 3. Inflammatory response and cells involved in inflammatory cascade. * shows the 
steps that provide evidence that flavonoids can act to counteract the inflammatory response. 
 
Flavonoids can suppress the expression of the COX gene through interactions with cell signaling 
pathways, such as the protein kinase C, NF-κB and tyrosine kinase pathways [50–52]. Previous studies 
have reported that flavonoids inhibit of arachidonic acid blocking the cyclooxygenase and  
5-lipoxygenase pathways [53–56]. However, the mechanisms involved in this enzymatic inhibition are 
not fully elucidated.  
The anti-inflammatory effects of phenolic compounds are related to the ability in modulating the 
expression of pro-inflammatory genes, such as NOS, cyclooxygenase, lipoxygenase but also by acting 
throughout nuclear factor (NF-κB) signaling and mitogen-activated protein kinase [57,58] and 
activating the Nrf2/Keap1 pathway [59]. NF-κB has been reported as one of the most notable  
pro-inflammatory gene expression regulators and mediates several cytokines synthesis, such as TNF-α, 
IL-1β, IL-6, and IL-8 as well as COX-2 [60]. Previous studies have confirmed that flavonoids exert 
their anti-inflammatory effects by modulating the inflammatory cells, inhibiting the T lymphocyte 
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proliferation, inhibiting pro-inflammatory cytokines (TNF-alpha and IL-1), or controlling enzymes 
derived from the arachidonic acid pathway such as NO formation [10,61–65]. 
Studies have shown that the flavonols such as quercetin (18) and kaempferol (12) exhibit significant 
anti-inflammatory actions which are believed to be through the inhibition of the phospholipase A2 (via 
arachidonic acid), lipoxygenase, cyclooxygenase and tromboxane enzymes and through the modulation 
of iNOS thereby inhibiting NO production [57,66]. Other flavonoids, such as myricetin (17), hesperetin 
(6) and naringenin (2), also exhibit inhibitory activity of the enzyme phospholipase A2 [64]. 
The inhibition of iNOS and NO production is also attributed to other flavonoids such as apigenin 
(15), luteolin (19), chrysin (14), kaempferol (12) and genistein (42) [57,64,65]. The flavonols morin 
(22) and myricetin (17) also have inhibitory actions on the enzyme lipoxygenase, the flavones chrysin 
(14), apigenin (15), and luteolin (19) and the flavonols morin (22), galangin (23) and rutin (16) inhibit 
the enzyme cyclooxygenase [64,66,67]. Genistein (42), quercetin (18), luteolin (19), apigenin (15) and 
rutin (16) are capable to inhibit pro-inflammatory cytokines such as TNF-α and IL-1 [61,62,64]. 
Luteolin (19), apigenin (15), myricetin (17) and quercetin (18) are also able to modulate lymphocytes 
and neutrophils [68]. Additionally, it is known that quercetin (18) inhibits the activity of 
cyclooxygenase and lipoxygenase metabolites [69,70]. 
An in vitro study shows that the flavonoids luteolin (19), apigenin (15) and fisetin (24) are potent 
inhibitors of the synthesis of IL-4 and IL-13 [71]. Scutellarein (25), 3-hydroxyflavone (26), 
kaempferol (12), quercetin (18), eriodictyol (4), fustin (7) and 7-hydroxyflavone (27) also act to inhibit 
the production of IL–4 with hydroxylation at positions C-3, C-5 and C-7 being necessary to observe 
the maximum inhibition. However, the precise mechanisms by which these flavonoids act in the 
control of cytokine synthesis remains to be better elucidated [71]. 
Additionally, the effect of the double bond in the flavonoid structure on the anti-inflammatory 
action, including the inhibition of lymphocyte proliferation, iNOS, COX and PLA-2, has been 
determined [10]. Structurally, the delocalization of electrons generated by the extension of π 
conjugation in the structure of flavonoids (ketonic carbonyl at C-4 and C-2/C-3 double bond at ring C) 
allows greater stability of intermediate radical species which is involved in inflammation process. 
Furthermore, the presence of a catechol group at the B ring is important because this group promotes 
enzymatic oxidation, inducing the formation of quinone/semiquinone electrophilic species that are 
capable of performnucleophilic addition. Thus, ligands act as electrophiles of macromolecules  
(e.g., proteins), resulting in reactions involving the formation of covalent bonds between the flavonoids 
and biomacromolecules.  
Furthermore, the flavanone hesperetin (6) displayed a lower inhibitory activity of the enzyme 
phospholipase A2 (PLA2) compared with the flavonols kaempferol (12), quercetin (18) and myricetin 
(17). This finding once again highlights the importance of the double bond at positions C-2/C-3 (ring 
C) for anti-inflammatory activity [10]. According to Lattig et al. [72] in their study of molecular 
modeling, the double bond between positions C-2/C-3 induces coplanarity between rings A and C, 
favoring the interaction of the flavonoid with the enzymatic site receptor. 
Kim et al. [62] reported that the presence of hydroxyl groups at C-5 and C-7 (ring A) as well as at 
the C-3' and C-4' (ring B) positions is an important feature, while the glycosylation of these groups 
reduces the anti-inflammatory activity. Quercetin (18) and its glycoside derivative quercitrin (13) are 
an examples that reflect the importance of glycosylation. Both compounds inhibit the production of 
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PGE2 and LTB4 in an induced pleurisy model in rats, but quercitrin (13) showed lower activity than 
their aglycone. A study by Rotelli et al. [73] also shows that glycosylation affects anti-inflammatory 
activity the classic model of carrageenan-induced edema in the mouse paw. The results indicate that 
aglycones (quercetin, 18 and hesperetin, 6) gave positive results, while the glycosylated flavonoids 
showed no significant activity (rutin, 16 and hesperidin, 5).  
Another comparative study between pairs of glycosides/aglycones [74] showed that the addition of 
sugar residues significantly reduces anti-inflammatory activity, suggesting that the lipophilicity and 
bioavailability of tested compounds becomes an important factor. Holmann et al. [75] suggested that 
quercetin glycoside derivatives are more readily absorbed than the aglycone forms. Nevertheless, these 
aspects are not fully elucidated because the role of glycosylation of flavonoids in facilitating 
absorption is questioned by the fact that catechin (46), which is not glycosylated in nature, is absorbed 
more efficiently [12]. Therefore, these observations suggest that glycosyl derivatives appear to be more 
active than those in aglycone forms [76]. 
In general, the currently structural requirements for anti-inflammatory activity of flavonoids (Figure 4) 
are the unsaturation in the C ring (Δ2), the number and position of hydroxyl groups (for example, the 
catechol group at ring B), the carbonyl group at C-4, and non-glycosylation of the molecule. However, 
compounds that do not have these structural features (e.g., the flavonoid aglycone kaempferol (12), 
also display an anti-inflammatory activity by affecting the enzymes of the inflammatory cascade [68]. 
Figure 4. Structure of quercetin as example of important requisites (unsaturation in the  
C ring, number and position of hydroxyl groups at ring B, carbonyl group at C-4 and non-
glycosylation) for anti-inflammatory activity of flavonoids. 
 
5. The Role of Flavonoids in Lung Diseases 
5.1. General Aspects 
Generally, lung disease involves acute or chronic inflammation that culminates in a repair process 
of the lung and is highly associated with a decrement in lung function. Flavonoids have been 
frequently used in folk medicine and several studies have been conducted to prove that their effects are 
associated with anti-inflammatory and antioxidant properties, as described above. 
Recently, Lim et al. [77], evaluating the pharmacological action of a total extract of Morus alba on 
airway inflammation, found a reduction in the total number of inflammatory cells and a reduction in 
O
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TNF-α, IL-6 and NO production by lung macrophages. The crude extract also inhibited epithelial 
hyperplasia and alveolar space destruction in a model of airway inflammation. Therefore, treatment 
with antioxidant and anti-inflammatory drugs may be beneficial in inhibiting or reducing the 
progression of pulmonary disease in patients with COPD, lung cancer, acute respiratory distress 
syndrome (ARDS) and asthma. Additionally, some reports suggest that nutrition, with an emphasis on 
a high consumption of fruits and vegetables, rich in flavonoids and other antioxidant compounds, can 
be an important element of primary prevention of cancer [78]. 
5.2. Chronic Obstructive Pulmonary Disease (COPD) 
The incidence and severity of chronic obstructive pulmonary disease (COPD) is growing affecting 
between 100 and 150 million people worldwide, is related to a significant rate of mortality [79] 
occupying the fourth leading cause of death worldwide. COPD is characterized by persistent airflow 
limitation that is usually progressive and is associated with an enhanced chronic inflammatory 
response to noxious particles or gases in the airways and the lung [79]. The inhalation of cigarette 
smoke and other environmental pollutants stimulates the alveolar macrophages in the lung epithelial 
cells to generate reactive oxygen species (ROS) and reactive nitrogen species (RNS) in excess causing 
an imbalance in the system [80,81]. The inflammatory cells recruited by oxidative stress as well as the 
local epithelial cells produce matrix metalloproteinases (MMPs) in the lungs, which in excess can 
degrade the alveolar walls and lead to an increased air space and the development of emphysema [82]. 
Although the effort to understand the cellular and molecular mechanisms involved in the pathogenesis 
of COPD, these aspects are not well elucidated until now; it is believed that oxidative stress, chronic 
inflammation and an imbalance of proteases and antiproteases are involved in the development and 
evolution of the emphysema [80,81,83].  
Several flavonoids such as catechins, flavonols and flavones are positively associated with force 
expiratory volume in one second (FEV1) increment and inversely associated with symptoms such as 
chronic cough, shortness of breath (not chronic) and phlegm, suggesting a beneficial effect of ingestion 
of catechins in patients with COPD. Studies have shown beneficial effects of flavonoids, such as 
quercetin (18), on COPD and in the prevention of the progression of pulmonary emphysema in animal 
models [84]. 
Poly (ADP-ribose) polymerase (PARP)-1 is a nuclear enzyme involved in the pro-inflammatory 
signal transduction pathway of chronic obstructive pulmonary disease (COPD). In addition, oxidative 
stress is the main pathological mechanism in COPD. Therefore, an experiment evaluating several types 
of anti-inflammatory flavonoids—fisetin (24), morin (22), flavone (29) and tricetin (34)—was 
performed to examine the involvement of molecular signaling. Blood samples from patients diagnosed 
with COPD were pre-incubated with the flavonoids and then exposed to LPS: the concentration of 
TNF-α, IL-6, IL-8 and IL-10 were then measured. Tricetin (34) and fisetin (24) were the most efficient 
treatment for attenuating LPS-induced increases of TNF-α. These flavonoids were also able to 
attenuate cytokine release from leukocytes, thus making the PARP-1-inhibiting compounds potential 
nutraceutical agents for patients with the COPD [85]. 
Quercetin (18), another widely studied flavonoid [86–90], has been assessed for the release of 
elastase that is the major product secreted by neutrophils, which are cells associated with the innate 
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immune system. When stimulated, neutrophils release elastase, which is mainly responsible for 
degrading foreign proteins during phagocytosis. Though imbalanced, the nonspecific enzyme release 
can damage cell membranes and extracellular space proteins such as elastin, fibronectin and eoglycans, 
causing several inflammatory diseases such as respiratory distress syndrome, pulmonary emphysema 
and ARDS [91]. In an evaluation of immunomodulatory activity evaluation, along myricetin (17), 
kaempferol (6) and quercetin (18) proved to be the most potent inhibitors of elastase release, 
suggesting, a therapeutic use for neutrophil-dependent inflammatory diseases [92].  
Furthermore, it is well-accepted that quercetin (18) has a protective effect on cells, the 
cytoprotective mechanism of which has been extensively investigated. This flavonoid upregulates 
endogenous defensive pathways and activates specific transcriptional factors. A study performed with 
the LA-4 cell line substantiated the findings that quercetin (18) increases in the levels of heme 
oxygenase (HO)-1 expression, protecting cells from the H2O2 apoptotic effects, such as hypodiploid 
cells, the activation of caspase 3 enzyme activity and lactate dehydrogenase release. Therefore, 
quercetin (18) successfully attenuates oxidative epithelial cell injury in lung inflammation [88]. 
The modulatory effect of quercetin (18) on protein expression has also been investigated for 
cytoprotection in airway inflammatory diseases. In human epithelial cells (HBE16), the effect of this 
flavonoid on mucin 5AC (MU5AC) expression induced by human neutrophil elastase was evaluated [37]. 
Quercetin (18) reduced both gene transcription and protein expression of MUC5AC in a dose-dependent 
manner and also markedly decreased mRNA and protein expression of epidermal growth factor 
(EGFR). Phosphorylated ERK 1/2 which was significantly increased with HNE treatment, was also 
decreased by quercetin (18), as was pPKC HNE-induced protein expression. Altogether, quercetin (18) 
most likely intervenes in the PKC/EGFR/ERK signal transduction pathways to inhibit HN-induced 
MUC5AC expression in human airway epithelial cells, making this flavonoid a potential treatment for 
counteracts mucus hypersecretion in chronic inflammatory airway disease [89]. 
Moreover, quercetin (18) exhibits anti-inflammatory effects in addition to the inhibition of protein 
tyrosine and serine/threonine kinases [93]. This flavonoid has been shown to reduce inflammation and 
lung expression of MMP9 and MMP12, by increasing type III deacetylase protein Sirt-1 expression, a 
down-regulator of MMP both in vivo and in vitro [94]. Furthermore, this flavonoid was effective in 
improving the elasticity of the lung and prevented the progressive loss of elastic recoil and subsequent 
progression of emphysema, but did not stimulate the regeneration of damaged alveoli.  
The flavonoid liquiritin apioside (9) was evaluated in the human type II alveolar epithelial cell line 
(A 549) for protective effects against cigarette smoke-mediated oxidative stress. Treatment with this 
flavonoid resulted in a concentration-dependent prevention of cigarette smoke extract (CSE)-induced 
cytotoxicity, an increase of TGF-β and TNF-α mRNA expression, depletion of glutathione (GSH) and 
cell apoptosis. In treated ICR mice, this flavonoid displayed dose-dependent inhibition of pulmonary 
neutrophils and macrophage inflammation and inhibited the presence of mucus-containing globet cells 
in the proximal airways. Moreover, TGF-β and TNF-α release and myeloperoxidase activity induced 
by chronic smoke was attenuated, whereas the superoxide dismutase activity was improved [95]. These 
authors suggested that the liquiritin apiodise (45) protects lung epithelial cell injury induced by 
cigarette smoke by inhibiting TGF-β and TNF-α and increasing the GSH levels, suggesting a potential 
role as an agent against epithelial damage in COPD. 
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The flavonoid baicalin (33) was also tested in COPD, a condition considered insensitive to 
corticosteroids therapies. This flavonoid was able to reduce inflammation by decreasing inflammatory 
cells and the production of TNF-α, IL-8 and MMP-9 in BalB/C mice submitted to cigarette smoke 
exposures, results that were not achieved by the positive control group treated with the synthetic 
corticosteroid dexamethasone. 
5.3. Acute Respiratory Distress Syndrome (ARDS)  
ARDS is a common disease in the Intensive Care Unit (ICU), characterized by increased infiltration 
of inflammatory cells (mainly neutrophils), by the production of inflammatory mediators, such as 
TNF- and of reactive oxygen species (ROS), tissue edema and extracellular matrix remodeling [96]. 
ARDS is mainly associated with lung infection but also has extra-pulmonary causes. Although the 
control of lung ventilation as a protection strategy has considerably reduced mortality, no specific 
treatment is available; the number of young people who died because of ARDS is high and the 
treatment only considered the cause. Some evidence suggests that substances of the flavonoid class 
may have a modulatory effect in ARDS, but most of the studies are in experimental models [97,98].  
Models of lipopolysaccharide-induced lung inflammation are also used to study the anti-inflammatory 
effects of flavonoids because LPS is present in the membrane of gram-negative bacteria and LPS is 
considered one of the main risk factors for ARDS [97]. In a study evaluating the protective activity of 
the flavonoid luteolin (19) in animals that received LPS to mimic ARDS, authors showed an important 
reduction of lung hemorrhage, neutrophilic inflammation as well as interstitial edema in distal lung 
parenchyma and alveolar spaces [99]. The reduction of catalase activity, superoxide dismutase activity, 
oxidative damage and lipid peroxidation has also been achieved in lung tissues after luteolin (19) 
pretreatment and LPS challenge. Moreover, the authors also found a reduction in TNF-α, KC and 
ICAM-1 content in BALF cells induced by luteolin (19). Regarding the mechanism of action, this 
flavonoid reduced LPS-induced activation of the MAPK and NFκB pathways [99]. Other works have 
also studied flavonoids for their beneficial effects in LPS-induced ARDS [97]. 
The protective effect of kaempferol (12), as well as its mechanism of action, has been evaluated in 
LPS-induced ARDS. This flavonoid, administered to BALB/c mice intragastrically attenuated 
pulmonary edema, markedly decreased lung wet-to-dry ratio, and decreased protein concentration and 
inflammatory cells in BALF. Through histological studies was possible to find that this flavonol 
substantially attenuated alveolar wall thickness and hemorrhage as well as inflammatory cells 
infiltration in lung parenchyma induced by LPS; however, superoxide dismutase activity increased. It 
was suggested that the mechanism of kaempferol’s (12) benefic effect in LPS-induced ARDS was via 
the controlling of the MAPK and NF-B signaling pathways, with inhibition of tissue oxidative stress 
and pulmonary inflammatory response most likely involved as well [100]. Acting on toll-like receptor 
4 (TLR4), a < 20 μM concentration of nontoxic kaempferol (12) attenuated the LPS-induced IL-8 
release and inhibited eotaxin-1 induction as well [101] 
The flavanone pinocembrin (10) has been assessed for its therapeutic effects in LPS-induced 
ARDS. In a murine model, the pulmonary edema, histological severity, neutrophilic, lymphocytic and 
macrophagic infiltrations were attenuated. Pretreatment using pinocembrin (10) also decreased the 
concentrations of TNF-α, IL-1 β, IL-6 and increased IL-10 levels. Parallel in vitro experiments 
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suggested that the mitigation of LPS-induced ARDS by this flavonoid is a result of the suppression of 
Iκ α, JNK and p38MAPK activation [102]. 
Also assessed in LPS-induced lung inflammation, the flavonoid oroxylin-A (32) has been tested for its 
beneficial anti-inflammatory effects in in vivo experiments. Isolated from Scutellaria baicalensis [103], this 
compound mitigated reduced inflammation, elevated levels of TNF-α and NO in the plasma, alveolar 
edema and thickened alveolar septa through a post-treatment administration. Altogether, oroxylin-A 
(32) proved to be a potential drug for ameliorating lung inflammation induced by LPS [98]. 
Additionally, the anti-inflammatory and antioxidant protective properties of quercetin (18) were 
assayed against pneumotoxic substances that cause lung injury. Paraquat (PQ: 1,1'-dimethyl-4-4'-
bipyridinium) is thought to induce pulmonary damage via reduction in redox cyclic, creating PQ  
cation radicals that result in oxidation of NADPH to NADP+ in association to superoxide anion and 
other oxygen free radicals [86]. An in vivo experiment the authors showed that exposure to PQ induced 
an elevated pulmonary malondialdehyde (MDA) levels, heme oxygenase-1 (HO-1) expression  
and total oxyradical scavenging capacity reduction. These alterations were inhibited by post-treatment 
with quercetin (18). This flavonoid treatment also significantly inhibited the NO, MDA and  
4-hydroxyproline (4-HP) elevation and pulmonary glutathione (GSH) reduction. Therefore, the 
antioxidant activity of quercetin (18) was most likely responsible for inhibiting the development of 
PQ-induced pulmonary injury [86]. 
Naringin (1), a flavanone derivative, was also tested for in paraquat-induced ARDS and pulmonary 
fibrosis. Daily treatment with naringin (1) highly increased survival rates in PQ exposed mice and 
improved, in a dose-dependent manner, increased leukocyte infiltration and the overexpression of 
TNF-α and TGF-β1 resulting from PQ challenge. Treatment with narigin (1) also reduced the  
PQ-induced upregulation of MMP-9 and its inhibitor TIMP-1, pulmonary malonaldehyde and 
hydroxyproline as well as pulmonary fibrosis. These features were associated to increased superoxide 
dismutase, glutathione peroxidase (GSH-Px) and heme-oxygenase (HO-1) activities. Therefore, 
naringin (1) is a flavonoid that exhibits effective protection against PQ-induced lung injury [104]. 
5.4. Asthma 
Asthma, a chronic airway inflammatory disorder, is a serious public health problem all over the 
world, [105]. Recurrent episodes of wheezing, chest tightness, breathlessness and coughing are present 
in patients with asthma which are associated to airway hyper-responsiveness and chronic airway 
inflammation. These episodes are usually associated with extensive, airflow obstruction within the 
lung that is frequently reversible either spontaneously or with treatment. There is an important role of 
cytokines in asthma which orchestrate the inflammatory response and determine the crisis severity. 
Several cytokines are involved in asthmatic physiopathology including Th2 classifical cytokines such 
as IL-5, IL-4 and IL-13, which are required for eosinophil differentiation and survival, for TH2 cell 
differentiation and for IgE formation.respectivelly. In addition, IL-1and TNF-, are also important 
and acts amplifying the inflammatory response, and GM-CSF, which prolongs airways eosinophil 
survival. Mast cells release mediators such as histamine which contributes to airway smooth muscle 
constriction and inflammation [106]. 
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Several studies have shown that food habits can influence to the development of allergic diseases. 
Devereux et al. [107] showed that low consumption of foods containing antioxidants such as fruits and 
vegetables may be associated with an increase in asthma and atopic diseases, while the ingestion of 
antioxidants and lipids during pregnancy and childhood can reduce the appearance of allergic diseases. 
A case-controlled, population-based study reported that the consumption of apples and red wine was 
negatively associated with the asthma prevalence or severity, possibly attributed to the beneficial effect 
of flavonoids [108]. In addition, these authors also suggested that an increase in the flavonoid ingestion 
decreases the incidence of asthma in the population.  
The anti-allergic capacity of flavonoids such as apigenin (15), luteolin (19), 3,6-dihydroxy-flavone 
(28), fisetin (24), kaempferol (12), quercetin (18), and myricetin (17) can be associated with a decrease 
in histamine release [35,109,110] through the inhibition of the chemical mediators and cytokine 
production by mast cells and with the suppression of the cysteinyl leukotriene synthesis through the 
inhibition of phospholipase (PLA2) and/or 5-lipoxygenase (5LO) [111]. However, the molecular 
mechanism involved is not totally clear. Townsend et al. [112] using tracheal rings in vitro, found an 
airway smooth muscle relaxation induced by quercetin (18) which also potentiates the relaxation 
effects of β-agonist via dual phosphodiesterase inhibition of prostaglandins. Additionally, an in vitro 
study evaluating the effects of kaempferol (12) in lung inflammation was conducted using the human 
airway epithelial BEAS-2B cell line found a reduction in inflammation. In addition, in an in vitro 
experiment, BALB/c OVA-sensitized mice were used to demonstrate the demoting effect of this 
flavonoid on asthmatic inflammation. Through oral administration, kaempferol (12) alleviated airway 
inflammation by modulating tyrosine kinase 2-STAT1/3 and IL-8, both for airway epithelium and in 
the asthmatic [101].  
The flavonoids fisetin (24) and morin (22) and kaempferol (12) have also been tested in asthma 
models both on the early response and in the late response. In ovalbumin sensitized guinea pigs, all 
three flavonols reduced the recruitment of total leukocytes. Histamine content, phospholipase A2 and 
EPO (eosinophil peroxidase) activity were also significantly inhibited by the flavonols. Kaempferol 
(12) treatment resulted in the greatest anti-asthmatic effect, and fisetin (24) treatment produced the 
highest inhibition of Raw (airway resistance). Such data suggests that the lower the molecular weight, 
the greater the beneficial effects on asthma of these compounds [113]. 
Other flavonoids such as quercetagetin (35), kaempferol-3-O-galactoside (36) and scutellarein (25) 
are phenolic compounds that acts inhibiting the PLA2 [56]. Cirsiliol (37) is able to inhibit by 99%,  
the activity of leukotrienes. In addition, quercetin (18), luteolin (19) and baicalein (30) were able to 
inhibit the secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) in cultures of 
human mast cells in response to the FcεRI44 crosslinker [114] besides counteracts the release of  
histamine, leukotriene and prostaglandin D2. These compounds also affect the release of IgE by bone 
marrow-derived cultures murine mast cell [115]. Studies performed in an in vivo model of allergic 
airway inflammation have shown that quercetin (18) acts as an inhibitor of TNF-α, thus reducing 
airway responsiveness [116], and also inhibits eosinophilic inflammation in asthmatic animals [117].  
Furthermore, flavonoids such as luteolin (19), apigenin (15) and fisetin (24) have been shown to 
significantly decrease the synthesis of IL-4, IL-13 and TNF-α synthesis [71,118–120], while 
isoquercitrin (38) and quercetin (18) reduce the recruitment of eosinophils and the formation of 
leukotrienes in an experimental asthma model in mice [117]. Moreover, luteolin (19), apigenin (15) 
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and fisetin (24) suppress the mRNA expression of IL-4, IL-13 and CD40 ligand as well as their 
respective protein activities, indicating that these flavonoids could act as natural inhibitors of IgE [71]. 
A study involving five flavonoids isolated from Glycyrrhiza uralensis (Gan-Cao), a Chinese plant, 
investigated the ability of the compounds to inhibit human fetal lung fibroblast (HFL-1) secretion of 
eotaxin-1 [118]. Liquiritigenin (8), isoliquiritigenin (45) and 7,4-dihydroxyflavone (31) proved to be 
effective in demonstrating anti-inflammatory activity [121]. Other flavonoids derived from the same 
species have been investigated for their protective effect against respiratory diseases. 
Genistein (42), a phytoestrogen belonging to the isoflavone class, has been studied in different 
conditions involving airway inflammation. Considered a broad-spectrum protein tyrosine kinase 
inhibitor, genistein (42) (15 mg/kg administered intraperitoneally to sensitized male Hartley guinea 
pigs) inhibited ovalbumin-induced acute bronchoconstriction and airway hyperresponsiveness to 
methacholine, eosinophilic inflammation both in BALF and in airways and eosinophil peroxidase 
activity in cell-free assays. The authors suggested that the inhibition of the tyrosine signaling cascade 
by via genistein (42) stimulus may present a therapeutic possibility for allergic airway diseases [122].  
Soy isoflavones containing high levels of genistein (42) (over 40%) and other derivatives, such as 
daidzein (44) and daidzin (43), were used in a murine model of allergic asthma. The oral 
administration of increase doses of soy isoflavones significantly attenuated OVA-induced AHR in 
response to intravenous methacholine and also reduced the eosinophils count in lung. Daily 
administration also markedly suppressed, in a dose dependent manner, the eotaxin, IL-5, IL-4 and 
matrix metalloproteinase-9 (MMP-9) mRNAs, augment the expression of interferon (IFN-γ) mRNA 
and the expression of tissue inhibitor of metalloproteinase-1 (TIMP-1). Moreover, these compounds 
also inhibit airway mucus production and extracellular matrix remodeling in lung tissues which can be 
observed through histological studies [123].  
Finally, due to the anti-inflammatory potential and antioxidant activity of sakuranetin (11) [124], 
our research group recently tested the effects of this flavonoid in models of lung disease [58]. We 
showed that sakuranetin (11) has a great potential to treat asthma since it reduced eosinophilic 
inflammation and reversed lung remodeling in mice. In addition, we demonstrated that these effects 
could be attributed to a reduction in Th2 cytokines (but not Th1 cytokines), oxidative stress and the 
control of NF-B activity. All of these effects contribute to reduce the airway hyperresponsiveness 
observed in this animal model. Preliminary studies also suggest that sakuranetin (11) reduces lung 
emphysema as well as neutrophilic and macrophage inflammation [125], suggesting a potential use of 
this compound in treat emphysema. Table 1 lists the main flavonoids that have displayed activity in 
lung inflammation and diseases. 
Table 1. Active flavonoids in lung inflammation and diseases. 
Flavonoid Lung Effect Reference 
Naringin (1) Anti-ARDS [104] 
Kaempferol (12)  
Anti-allergic 
Anti-ARDS 
Anti-asthmathic 
[35,109,110] 
[100] 
[101] 
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Table 1. Cont. 
Flavonoid Lung Effect Reference 
Apigenin (15) 
Anti-allergic 
Anti-asthmathic 
[35,109,110] 
[71,120] 
Genistein (42) Bronchoconstrictor [122] 
Daidzin (43) Bronchoconstrictor [123] 
Daidzein (44) Bronchoconstrictor [123] 
Myricetin (17) Anti-allergic [35,109,110] 
Quercetin (18) 
Preventing pulmonar emphysema 
Anti-allergic 
Anti-ARDS 
Anti-asthmathic 
[84] 
[35,109,110] 
[91] 
[89,114,117]  
Luteolin (19) 
Anti-allergic 
Anti-asthmathic 
Anti-COPD 
[35,109,110] 
[71,114,120] 
[97,99] 
Morin (22) 
Anti-asthmathic 
Anti-COPD 
[113] 
[85] 
Fisetin (24) 
Anti-allergic 
Anti-asthmathic 
Anti-COPD 
[35,109,110] 
[113] 
[85] 
Scutellarein (25) Anti-asthmathic [115] 
3,6-Dihydroxyflavone (28) Anti-allergic [35,109,110] 
Flavone (29) Anti-COPD [85]  
Tricetin (34) Anti-COPD [85]  
Quercetagetin (35) Anti-asthmathic [56] 
Kaempferol-3-O-galactoside 
(36) 
Anti-asthmathic [56] 
Cirsiliol (37) Anti-asthmathic [115] 
Baicalein (30) Anti-asthmathic [115] 
Isoquercitrin (38) Anti-asthmathic [71,117] 
Liquiritigenin (8) Anti-COPD [121] 
Isoliquiritigenin (45) Anti-COPD [121] 
7,4’-Dihydroxyflavone (31) Anti-COPD [121] 
Liquiritin apioside (9) Anti-COPD [95] 
Pinocembrin (10) Anti-ARDS [102] 
Oroxylin-A (32) Act decreasing lung inflamattion  [98] 
Baicalin (33) Anti-COPD [126] 
Sakuranetin (11) Anti-asthmathic and COPD [58,125] 
6. Clinical Perspectives of Flavonoid Application in Lung Disease  
Although several studies have shown that different types of flavonoids are beneficial in controlling 
respiratory diseases, few have been performed in humans. As described in this review, the majority of 
the studies in humans are with asthmatic patients; there were no studies evaluating emphysematous 
patients and only a few evaluating ARDS patients. Notwithstanding the small number of reports, the 
results are promising because most of the studies revealed positive results of phytotherapy on lung 
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diseases. Kalhan et al. [127] showed that the asthmatic patients receiving a soy isoflavone supplement 
for four weeks exhibited a reduction in exhaled NO and ex vivo production of leukotrienes by 
eosinophils obtained from the blood of these patients. In addition, Smith [128] demonstrated that this 
flavonoid is associated with improved lung function in more than 1,000 patients studied. Most studies 
suggest that the mechanism of action of flavonoids is through the inhibition of NF-kB. Despite of these 
results, additional studies of the specific effects of flavonoids on molecular mechanisms in lung 
diseases and studies evaluating toxic adverse effects especially in humans are need.  
7. Conclusions  
In this review, we report that the main effect of flavonoids in lung disease could be attributed to an 
antioxidant and anti-inflammatory effect. Inflammation is involved in all lung diseases, and its 
inhibition could ameliorate lung function as well as avoid lung remodeling. Several flavonoids have 
been tested in experimental models and were found to be beneficial, mainly by inhibiting cytokines 
associated with the down-regulation of several transcription factors. Generally, the key structural 
features of active flavonoids are unsaturation in the C ring (2), the number and position of hydroxyl 
groups at the A and B rings, the carbonyl group at C-4 at ring C and frequently, non-glycosylation of 
the molecule. Taking these features into consideration, one may infer that natural products such as 
flavonoids may possibly be useful as prototypes in the development of novel substances for the 
treatment of several lung illnesses. However, further investigation is needed to evaluate the precise 
mechanisms of action and to determine if these results can be applied to diseases in humans.  
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